Biotech entity
The clearest coverage concentration is pharma: 7 of 10 stories, with the rest divided among 2 other categories. That works out to roughly 0.4 stories per week across a 159-day span. The busiest single day carried 2. Negative sentiment reaches 10% here, compared with 18% across the 613-story beat baseline for the same window.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 7 of 10 stories, with the rest divided among 2 other categories. That works out to roughly 0.4 stories per week across a 159-day span. The busiest single day carried 2. Negative sentiment reaches 10% here, compared with 18% across the 613-story beat baseline for the same window. Of the tracked stories, 2 of 10 also mention Keytruda, the most common co-covered peer. They are less corroborated than the beat average, carrying 3.3 original sources each against 3.7 for the same window. At 6.4, the average consequence score sits above the same-window beat average of 6.2. This profile follows 10 Biotech stories mentioning Novartis across the period from February 19, 2026 to July 27, 2026.
Computed from the 10 stories linked to this entity, with beat comparisons drawn from all 613 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Novartis. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Expiry
Merck faces biosimilar competition for its top-selling immunotherapy drug.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
Data Review
Expected first quarterly report on screening uptake and identification rates in Scotland.
Part 2 Expansion
Full global enrollment for efficacy endpoints (rPFS and OS) expected to accelerate.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Acquisition Announced
Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout.
Q4 2025 Earnings
Reported year-end financial results and updated 2027 cash runway.
Primary Objectives Met
Telix announces Part 1 achieved all primary safety and dosimetry goals.
Q4 2025 Earnings
Both companies report full-year 2025 results and 2026 guidance.
Scotland Launch
Scotland officially begins nationwide screening for all newborns.
Novartis Settlement
Novartis announces a confidential settlement with the Henrietta Lacks estate.
Anticipated Milestone
Expected Phase 1 data readout for MRT-6160 in autoimmune diseases.
Part 1 Completion
Enrollment for the safety and dosimetry portion of the study concludes.
Olpruva Scaling
Zevra reports steady growth in urea cycle disorder market share.
MRT-2359 Update
Released preliminary Phase 1 safety and target engagement data.
Novartis Expansion
Voyager expands its capsid discovery collaboration with Novartis.
Novartis Partnership
Signed global licensing deal for MRT-6160 worth up to $2.1B.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC treatment.
Ultragenyx Settlement
Ultragenyx settles with the estate over HeLa cell usage in gene therapy research.
Trial Initiation
ProstACT GLOBAL Phase 3 study begins enrollment.
A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Source: prnewswire.com · finanznachrichten.de
A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.
Source: maitlandmercury.com.au · ulladullatimes.com.au
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Scotland has officially become the first nation in the United Kingdom to implement routine newborn screening for Spinal Muscular Atrophy (SMA). This landmark public health initiative aims to identify the rare genetic condition within days of birth, enabling immediate access to life-saving gene therapies before irreversible muscle wasting occurs.
Monte Rosa Therapeutics reported quarterly results highlighting a robust cash position following its $2.1 billion Novartis partnership. The company is accelerating its molecular glue degrader pipeline with a strategic pivot toward high-value immunology indications.
Source: themarketsdaily.com · tickerreport.com
Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion.
Voyager Technologies and Zevra Therapeutics are preparing to report Q4 2025 results, highlighting a pivotal period for gene therapy platforms and rare disease commercialization. Investors are focused on Voyager's partnership revenue and Zevra's initial market traction for its newly approved NPC treatment.
Novartis has reached a confidential settlement with the estate of Henrietta Lacks, ending litigation over the unauthorized use of her 'immortal' HeLa cells. This marks the latest in a series of legal victories for the Lacks family against pharmaceutical giants that profited from cells taken without consent in 1951.
The Juvenile Idiopathic Arthritis (JIA) market is set for a decade of steady growth, projected at a 5.6% CAGR as advanced biologics from Bristol-Myers Squibb, Novartis, and UCB enter the pediatric space. With the 7MM market valued at $2.3 billion in 2025, the shift toward targeted therapies like SOTYKTU and BIMZELX is expected to redefine treatment standards for an estimated 173,000 patients by 2036.
Source: weeklyvoice.com · admin (in)
Novartis is linked from 10 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
